<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588923</url>
  </required_header>
  <id_info>
    <org_study_id>SHC005-I-03</org_study_id>
    <nct_id>NCT03588923</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sanhome Pharmaceutical, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sanhome Pharmaceutical, Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and&#xD;
      antiviral activity of single and multiple ascending doses of SH229 in patients with chronic&#xD;
      hepatitis C Virus infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are&#xD;
      400, 600, and 800 mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2018</start_date>
  <completion_date type="Actual">August 10, 2018</completion_date>
  <primary_completion_date type="Actual">August 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral effects of SH229, as measured by HCV RNA levels</measure>
    <time_frame>up to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration(Tmax)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration(Cmax)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life time(t1/2)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC)</measure>
    <time_frame>up to Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SH229 (400 mg) or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SH229 (600 mg) or matching placebo, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SH229 (800 mg) or matching placebo, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH229</intervention_name>
    <description>tablet, oral, 400 mg once daily for 3 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH229</intervention_name>
    <description>tablet, oral, 600 mg once daily for 3 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH229</intervention_name>
    <description>tablet, oral, 800 mg once daily for 3 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>tablet, oral, once daily for 3 days</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are willing to voluntarily take effective contraceptive measures from&#xD;
             screening to 6 months after the last dose;&#xD;
&#xD;
          -  18-65 years of age;&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50&#xD;
             kg for males and ≥45 kg for females;&#xD;
&#xD;
          -  No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as&#xD;
             Boceprevir, Telaprevir, Simeprevir, Sofosbuvir, Daclatasvir, Asunaprevir;&#xD;
&#xD;
          -  No antiviral treatment such as immune modulators, thymosin or other immune stimulating&#xD;
             factors, interferon, or Chinese herbs in the past 6 months;&#xD;
&#xD;
          -  HCV RNA ≥10*5 IU/mL at screening (Roche COBAS Taqman);&#xD;
&#xD;
          -  Chronic genotype 1-6 HCV Infection;&#xD;
&#xD;
          -  Serum ALT ≤10 times ULN;&#xD;
&#xD;
          -  FibroScan score ≤17.5kPa within 6 months before screening or at screening, or absence&#xD;
             of cirrhosis within 12 months before screening;&#xD;
&#xD;
          -  Subjects are capable of understanding and complying with the protocol and have signed&#xD;
             the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoke more than 5 cigarettes per day within three months prior to screening;&#xD;
&#xD;
          -  Subjects allergic to the study drug (including its excipients) or subjects who are&#xD;
             prone to allergies;&#xD;
&#xD;
          -  History of drug and/or alcohol abuse (alcohol consumption exceeding 14 units per week:&#xD;
             1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);&#xD;
&#xD;
          -  Blood donation or massive blood loss (&gt; 450 mL) within three months prior to&#xD;
             screening;&#xD;
&#xD;
          -  History of any non-HCV liver diseases, including but not limited to hemochromatosis,&#xD;
             primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic&#xD;
             hepatitis, non-alcoholic steatohepatitis, etc.;&#xD;
&#xD;
          -  Subjects with dysphagia or with any gastrointestinal disorders (or postoperative&#xD;
             conditions) that may affect the study drug absorption;&#xD;
&#xD;
          -  Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids,&#xD;
             acute gastritis, or gastric and duodenal ulcers;&#xD;
&#xD;
          -  Use of any drugs that alter liver enzyme activity within 28 days prior to screening;&#xD;
&#xD;
          -  Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal&#xD;
             medicines within 14 days prior to screening;&#xD;
&#xD;
          -  Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous&#xD;
             activities or other factors that may affect the disposition of the study drug within 2&#xD;
             weeks prior to screening;&#xD;
&#xD;
          -  Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as&#xD;
             itraconazole, ketoconazole or dronedarone;&#xD;
&#xD;
          -  Subjects with major changes in diet or exercise habits recently;&#xD;
&#xD;
          -  Participation in other clinical trials within three months prior to enrollment;&#xD;
&#xD;
          -  Electrocardiogram abnormalities with clinical significance;&#xD;
&#xD;
          -  Laboratory tests with clinical significance or other clinical findings that indicate&#xD;
             clinically significant diseases not associated with HCV infection (including but not&#xD;
             limited to gastrointestinal, renal, hepatic, neurologic, hematological, endocrine,&#xD;
             pulmonary, psychiatric, cardiovascular diseases);&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Creatinine clearance ≤ 60 mL/min;&#xD;
&#xD;
          -  Evidence of co-infection with HBV, HIV, or syphilis;&#xD;
&#xD;
          -  Child-Pugh Grade B or C;&#xD;
&#xD;
          -  Clinically significant hepatic decompensation including but not limited to, hepatic&#xD;
             encephalopathy, hepatocellular carcinoma, variceal bleeding, ascites, etc.;&#xD;
&#xD;
          -  Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours&#xD;
             prior to dosing;&#xD;
&#xD;
          -  Use of products containing alcohol within 24 hours prior to dosing;&#xD;
&#xD;
          -  Subjects with urine drug screening test positive, or with history of drug abuse in the&#xD;
             past 5 years;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanhua Ding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phase I Clinical Trial Unit, The First Hospital of Jilin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase I Clinical Trial Unit, The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>NS5B</keyword>
  <keyword>SH229</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

